Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.The Journal of Allergy and Clinical Immunology|December 18, 2010
Tight junction defects in patients with atopic dermatitisAnna De Benedetto, Nicholas M Rafaels, Laura Y McGirt, et al.The Journal of Allergy and Clinical Immunology|January 23, 2023
The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in miceBarbara Yang, Hazel Wilkie, Mrinmoy Das, et al.JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.The Journal of Allergy and Clinical Immunology|June 10, 2021
Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factorsChristopher H Arehart, Michelle Daya, Monica Campbell, et al.Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.The Journal of Allergy and Clinical Immunology|January 15, 2019
Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions"Wendy F Davidson, Donald Y M Leung, Lisa A Beck, et al.Pageof 16